How Did Saluda Medical Boost Revenue 17% While Losses Widened 25%?

• Revenue up 17% to US$39.4 million driven by US implant growth and international sales
• Net loss increased 25% to US$66.8 million due to sales force expansion and one-time expenses
• Completed ASX IPO raising US$152.3 million, converting preferred stock and convertible notes
• Cash used in operations rose slightly to US$60.3 million, with US GAAP financials reviewed without qualification